Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today
announces the review of medical technologies guidance from the UK National
Institute for Health and Care Excellence (NICE) for its PICO Single Use Negative
Pressure Wound Therapy System (sNPWT).
NICE have reviewed 'Medical Technology Guideline 43 PICO negative pressure wound
dressings for closed surgical incisions' which recognises that Smith+Nephew's
PICO sNPWT provides better clinical outcomes than standard dressings in patients
at high risk of surgical site infections (SSIs), at similar overall cost. As a
result, NICE has reconfirmed its guidance, that PICO sNPWT should be considered
as an option for closed surgical incisions in patients who are at high risk of
surgical site infections,(1) remains the same. Key high risk factors include a
high body mass index (BMI), diabetes, renal insufficiency and smoking among
others.(2)
In the recent NICE review, a total of 28 papers published after the original
guidance were identified. These included 12 Randomised Control Trials (RCT), 1
Uncontrolled Randomised Trial, 8 cohort studies, 3 before and after studies, and
4 economic studies. The 24 clinical studies included a total of 7,790 patients
with PICO sNPWT being used in 3,754.
NICE concluded that PICO sNPWT is associated with fewer SSIs and seromas
compared with standard wound dressings. Cost modelling suggests that compared
with standard wound dressings, PICO sNPWT provides extra clinical benefits at
similar overall cost to the NHS.(1) For some types of surgery, such as
colorectal, cardiothoracic and vascular surgery PICO sNPWT provides cost
savings.(1)
The PICO sNPWT dressing includes a proprietary AIRLOCK(?) Technology layer that
delivers negative pressure wound therapy across a surgical incision and the
surrounding zone of injury.(3,4) This unique feature is designed to help reduce
the risk of wound complications by reducing post-operative fluid(5,6) and
tension(*7) around a closed surgical incision. The combination of these actions
helps reduce the risk of two common surgical site complications - surgical wound
dehiscence and SSIs.(8)
"It's fitting that this recognition from NICE occurs during International
Cesarean Awareness Month, as PICO sNPWT has been shown to help reduce the risk
of SSI's for high-risk C-section patients,(**9-11 )said Simon Tarry, Senior Vice
President and General Manager, Advanced Wound Management for International
Markets at Smith+Nephew. "PICO sNPWT provides significant productivity
opportunities for healthcare systems, and improved outcomes for patients. We
hope this recognition will help Smith+Nephew support our customers to achieve a
new standard of care to reduce the growing burden of wound care on patients and
health care professionals."
To learn more about the NICE recommendations and PICO sNPWT please visit:
www.nice.org.uk/guidance/mtg43/evidence
(http://www.nice.org.uk/guidance/mtg43/evidence)
- ends -
Enquiries
Media
Dave Snyder +1 (978) 749-1440
Smith+Nephew
* as demonstrated in biomechanical modelling
** compared to conventional dressings/standard care
References

  1. NICE Medical Technology Guidance MTG43. PICO Negative Pressure Wound
     Dressings for closed surgical incisions. May 9th 2019
  2. World Union of Wound Healing Societies (WUWHS) Consensus Document. Closed
     surgical incision management: understanding the role of NPWT. Wounds
     International, 2016
  3. Casey C. Consistent delivery of therapeutic negative pressure levels by a
     single use negative pressure wound therapy system (sNPWT)* in a wound
     model. Paper presented at: EWMA; 2019; Gothenburg, Sweden.
  4. Smith+Nephew 2021.PICO(TM) Pressure Mapping Study. Internal Report.
     DS/19/211/R - Part B.

5. Karlakki SL, Hamad AK, Whittall C, et al.Incisional negative pressure wound

     therapy dressings (iNPWTd) in routine primary hip and knee arthroplasties:
     A randomised controlled trial. Bone Joint Res. 2016;5(8):328-337.
  6. Payne C, Edwards D.Application of the Single Use Negative Pressure Wound
     Therapy Device ( PICO ) on a Heterogeneous Group of Surgical and Traumatic
     Wounds. ePlasty. 2014:152-166.
  7. Loveluck J, Copeland, T., Hill, J., Hunt, A., and Martin, R.,
     .Biomechanical Modeling of the Forces Applied to Closed Incisions During
     Single-Use Negative Pressure Wound Therapy. ePlasty. 2016.
  8. Saunders C, Nherera LM, Horner A, Trueman P. Single-Use negative-pressure
     wound therapy versus conventional dressings for closed surgical incisions:
     systematic literature review and meta-analysis. BJS Open. 2021;0(0):1 - 8
  9. Hyldig N, Vinter CA, Kruse M, et al. Prophylactic incisional negative
     pressure wound therapy reduces the risk of surgical site infection after
     caesarean section in obese women: A pragmatic randomised clinical trial.
     BJOG. 2019;126:628-635.

10. Saunders C, et al. A single use negative pressure system reduces surgical

     site complications compared with conventional dressings in closed surgical
     incisions: a systematic literature review with meta-analysis. Poster

presented at the European Wound Management Association annual meeting, June 5-7, 2019, Gothenburg, Sweden.
11. NICE (2019) PICO negative pressure wound dressings for closed surgical
incisions (online) accessible from: https://www.nice.org.uk/guidance/mtg43. (Last accessed: Sept 2023)
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair,
regeneration and replacement of soft and hard tissue. We exist to restore
people's bodies and their self-belief by using technology to take the limits off
living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this
mission every day, making a difference to patients' lives through the excellence
of our product portfolio, and the invention and application of new technologies
across our three global business units of Orthopaedics, Sports Medicine & ENT
and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and
generated annual sales of $5.5 billion in 2023. Smith+Nephew is a constituent of
the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to
refer to Smith & Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com
(http://www.smith-nephew.com/)and follow us on X
(http://www.twitter.com/smithnephewplc), LinkedIn
(http://www.linkedin.com/company/smith-%26-nephew), Instagram
(https://www.instagram.com/smithnephewmeded/) or Facebook
(http://www.facebook.com/smithnephewplc).
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth and trading
profit margins, market trends and our product pipeline are forward-looking
statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-
placed", "believe", "estimate", "expect", "target", "consider" and similar
expressions are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks, uncertainties and
other important factors that could cause actual results to differ materially
from what is expressed or implied by the statements. For Smith+Nephew, these
factors include: conflicts in Europe and the Middle East, economic and financial
conditions in the markets we serve, especially those affecting healthcare
providers, payers and customers; price levels for established and innovative
medical devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product defects or recalls
or other problems with quality management systems or failure to comply with
related regulations; litigation relating to patent or other claims; legal and
financial compliance risks and related investigative, remedial or enforcement
actions; disruption to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including acquisitions
and disposals, our success in performing due diligence, valuing and integrating
acquired businesses; disruption that may result from transactions or other
changes we make in our business plans or organisation to adapt to market
developments; relationships with healthcare professionals; reliance on
information technology and cybersecurity; disruptions due to natural disasters,
weather and climate change related events; changes in customer and other
stakeholder sustainability expectations; changes in taxation regulations;
effects of foreign exchange volatility; and numerous other matters that affect
us or our markets, including those of a political, economic, business,
competitive or reputational nature. Please refer to the documents that
Smith+Nephew has filed with the U.S. Securities and Exchange Commission under
the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's
most recent annual report on Form 20-F, which is available on the SEC's website
at www. sec.gov, for a discussion of certain of these factors. Any forward-
looking statement is based on information available to Smith+Nephew as of the
date of the statement. All written or oral forward-looking statements
attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does
not undertake any obligation to update or revise any forward-looking statement
to reflect any change in circumstances or in Smith+Nephew's expectations.
(? )Trademark of Smith+Nephew. Certain marks registered in US Patent and
Trademark Office 42690 GLOBAL
Â